US 10,647,717 B2 · N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use

N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use

AssigneesAbbVie S.á.r.l., Galapagos NV

InventorsRhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Matthieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Steven Emiel Van der Plas, Xueqing Wang, Ann de Blieck

Life of this patent

Estimating the term…

Abstract

The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Claims3

Dependent claims

A compound, which is

wherein one or more hydrogen atoms are replaced by tritium;
or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application

16/444,495Filed 18 Jun 2019 · continuation

Priority

9 Oct 2015

Published

US 2019/0202823 A131 Oct 2019

Granted

12 May 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification28 codes

C07D 471/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61K 31/437
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring…
A61K 31/4545
Containing further heterocyclic ring systems: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/506
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: not condensed and containing further heterocyclic rings

Family

Application62/239,647Us provisional application · filed 9 Oct 2015

Application62/309,794Us provisional application · filed 17 Mar 2016

Application15/287,911Parent of this continuation · filed 7 Oct 2016

Application15/843,917Parent of this continuation · filed 15 Dec 2017

US 9,890,158 B2Parent of this continuation · filed 13 Feb 2018

Application16/293,973Parent of this continuation · filed 6 Mar 2019

US 10,259,810 B2Parent of this continuation · filed 16 Apr 2019

US 2019/0330207 A1Pre-grant publication · published 31 Oct 2019

US 2017/0101405 A1Published application

US 2018/0105522 A1Published application

US 2019/0202823 A1Published application

US 10,647,717 B2This patent

From the US filing history. Foreign family members aren’t listed.